Overview

* Johnson & Johnson ( JNJ ) Q3 sales rise 6.8% to $24 bln, beating analyst expectations

* Adjusted EPS for Q3 at $2.80, surpassing analyst estimates

* Company raises full-year 2025 sales outlook to $93.7 bln

Outlook

* Johnson & Johnson ( JNJ ) raises full-year 2025 sales guidance to $93.7 bln

* Company reaffirms full-year adjusted EPS guidance at $10.85

* Johnson & Johnson ( JNJ ) focuses on growth in Oncology, Immunology, and other key areas

Result Drivers

* INNOVATIVE MEDICINE - Growth driven by Oncology products like DARZALEX and RYBREVANT, and Immunology products like TREMFYA, despite offset from STELARA

* MEDTECH GROWTH - Driven by cardiovascular products like Abiomed and Shockwave, and surgical products

* INNOVATION - Significant product approvals and submissions, including INLEXZO and TREMFYA, contributed to growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Beat $23.99 $23.71

bln bln (15

Analysts

)

Q3 Beat $2.80 $2.75

Adjusted (16

EPS Analysts

)

Q3 EPS $2.12

Q3 Beat $6.80 $6.63

Adjusted bln bln (13

Net Analysts

Income )

Q3 Net $5.15

Income bln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Johnson & Johnson ( JNJ ) is $190.00, about 0.5% below its October 13 closing price of $190.90

* The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)